Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B

Author(s):  
Hui‐Han Hu ◽  
Wen‐Juei Jeng ◽  
Mei‐Hung Pan ◽  
Wun‐Sheng Luo ◽  
Chia‐Ling Chang ◽  
...  
2017 ◽  
Vol 16 (6) ◽  
pp. 8556-8562 ◽  
Author(s):  
Dongsheng Wang ◽  
Qin Du ◽  
Guangcheng Luo ◽  
Qiang Wang ◽  
Guangrong Wang ◽  
...  

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 216 ◽  
Author(s):  
Sayeh Ezzikouri ◽  
Mohammad Enamul Hoque Kayesh ◽  
Soumaya Benjelloun ◽  
Michinori Kohara ◽  
Kyoko Tsukiyama-Kohara

Despite the availability of an effective preventive vaccine for hepatitis B virus (HBV) for over 38 years, chronic HBV (CHB) infection remains a global health burden with around 257 million patients. The ideal treatment goal for CHB infection would be to achieve complete cure; however, current therapies such as peg-interferon and nucleos(t)ide analogs are unable to achieve the functional cure, the newly set target for HBV chronic infection. Considering the fact functional cure has been accepted as an endpoint in the treatment of chronic hepatitis B by scientific committee, the development of alternative therapeutic strategies is urgently needed to functionally cure CHB infection. A promising target for future therapeutic strategies is immune modulation to restore dysfunctional HBV-specific immunity. In this review, we provide an overview of the progress in alternative therapeutic strategies, including immune-based therapeutic approaches that enhance host innate and adaptive immunity to achieve and increase the functional cure from CHB infection.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Sylwia Osuch ◽  
Tomasz Laskus ◽  
Hanna Berak ◽  
Karol Perlejewski ◽  
Karin J. Metzner ◽  
...  

Abstract During chronic hepatitis C virus (HCV) infection, both CD4+ and CD8+ T-cells become functionally exhausted, which is reflected by increased expression of programmed cell death-1 (PD-1) and T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), and elevated anti-inflammatory interleukin 10 (IL-10) plasma levels. We studied 76 DAA-treated HCV-positive patients and 18 non-infected controls. Flow cytometry measured pretreatment frequencies of CD4+PD-1+, CD4+PD-1+Tim-3+ and CD8+PD-1+Tim-3+ T-cells and IL-10 levels measured by ELISA were significantly higher and CD4+PD-1−Tim-3− and CD8+PD-1−Tim-3− T-cells were significantly lower in patients than in controls. Treatment resulted in significant decrease of CD4+Tim-3+, CD8+Tim-3+, CD4+PD-1+Tim-3+ and CD8+PD-1+Tim-3+ T-cell frequencies as well as IL-10 levels and increase in CD4+PD-1−Tim-3− and CD8+PD-1−Tim-3− T-cells. There were no significant changes in the frequencies of CD4+PD-1+ T-cells, while CD8+PD-1+ T-cells increased. Patients with advanced liver fibrosis had higher PD-1 and lower Tim-3 expression on CD4+T-cells and treatment had little or no effect on the exhaustion markers. HCV-specific CD8+T-cells frequency has declined significantly after treatment, but their PD-1 and Tim-3 expression did not change. Successful treatment of chronic hepatitis C with DAA is associated with reversal of immune exhaustion phenotype, but this effect is absent in patients with advanced liver fibrosis.


Medicine ◽  
2017 ◽  
Vol 96 (20) ◽  
pp. e6807 ◽  
Author(s):  
Xinhuan Wei ◽  
Hongshan Wei ◽  
Wei Lin ◽  
Zhongjie Hu ◽  
Jing Zhang

2021 ◽  
Author(s):  
Hannah S.J. Choi ◽  
Alexander Tonthat ◽  
Harry L.A. Janssen ◽  
Norah A. Terrault

Sign in / Sign up

Export Citation Format

Share Document